ASCRS and the Alliance of Specialty Medicine Recommend Physician-Administered Drugs Covered Under Part B Not be Moved to Part D in Comments on Drug Plan

This week, ASCRS and the Alliance of Specialty Medicine sent a letter to the Department of Health and Human Services (HHS) expressing concerns on proposals about the Trump Administration’s drug pricing plan, “American Patients First,” which may adversely impact physicians and patients. Chiefly, we oppose the proposal to move drugs that are administered in the office from Part B to Part D. Many Part B drugs are injected or infused intravenously and would not be appropriate for a patient to administer at home or obtain from a pharmacy before an office visit. Furthermore, many Part B drugs are administered during surgical procedures and are currently bundled into the hospital outpatient or ambulatory surgery center facility fee, which would make it challenging for patients to acquire and pay for these drugs. We urged HHS to maintain coverage for physician-administered drugs and biologics under Medicare Part B. Additionally, we raised concerns about patients who do not have Part D plans and how they would access necessary medications.

ASCRS will be submitting a separate comment letter in the upcoming weeks. We will keep you updated.